Dec 01, 2021

VIRALEZE™ registered in Vietnam with launch this week (ASX Announcement)

VIRALEZE™ registered in Vietnam with launch this week (ASX Announcement)
  • VIRALEZE™ antiviral nasal spray has been registered for sale in Vietnam
  • VIRALEZE™ is being launched in Vietnam this week, having recently signed an initial supply contract for approximately 100,000 units
  • A further ongoing distribution agreement for additional larger orders of VIRALEZE™ in Vietnam is currently being finalised for subsequent orders and ongoing supply
  • VIRALEZE™ is a broad-spectrum antiviral nasal spray that contains SPL7013, which has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses, including inactivation of >99.9% of the Delta variant of SARS-CoV-2, in laboratory studies that have been published in international, peer reviewed journals

Melbourne, Australia; 1 December 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received confirmation that VIRALEZE™ antiviral nasal spray has been registered for sale in Vietnam. The product launch is scheduled to occur in Vietnam this week with product supplied under the initial supply distribution arrangements, with Australian-based Healthco Australia Pty Ltd (HealthCo), and Vietnam-based Truong Bao Land International Investment Company Limited (TBL). TBL will also utilise the local medical distribution networks in Vietnam, including Nam Thanh Trade and Medical Services Company Limited[1].

Vietnam, which has a population of approximately 98 million, is experiencing a significant Delta outbreak with ~50 per cent of its population fully vaccinated[2].

The launch of VIRALEZE™ in Vietnam this week is being supported by extensive promotional activities and will be attended by key health officials, healthcare leaders, and media. Given the impact of the current Delta outbreak in Vietnam, a portion of VIRALEZE™ from the initial supply orders will be donated to hospitals and other healthcare organisations in Vietnam. A further ongoing distribution agreement for additional larger orders of VIRALEZE™ is being finalised, which will allow subsequent  orders and ongoing supply in Vietnam.

Dr Jackie Fairley, Starpharma CEO commented: “Starpharma is pleased to have achieved another registration for VIRALEZE™, and we are excited to see the product launched in Vietnam this week This registration, the first in South East Asia, builds upon existing submissions as well as registrations already achieved in Europe, India and New Zealand, and we are expediting further regulatory submissions in multiple regions and countries.”

VIRALEZE™ is a broad-spectrum antiviral nasal spray. The antiviral agent in VIRALEZE™, referred to as SPL7013, has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses and multiple variants of SARS-CoV-2, including inactivation of >99.9% of the highly infectious Delta variant, in laboratory studies. VIRALEZE™ is applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane - that traps and irreversibly inactivates virus. Importantly, VIRALEZE™’s mechanism of action means that mutations of the spike protein that make SARS-CoV-2 more infectious, as occurred for the Delta strain, appear to make the virus more susceptible to trapping and blocking by SPL7013.

VIRALEZE™ is registered in Europe, Vietnam, India and New Zealand, and available in certain markets online. In addition to the supply and distribution arrangements in Vietnam, VIRALEZE™ is also partnered with LloydsPharmacy in the UK, ADMENTA Italia Group in Italy, and Starpharma is in advanced discussions with potential commercial partners elsewhere in Europe, Asia, India, and other regions. VIRALEZE™ is not registered for sale or supply in Australia.

Starpharma acknowledges the $1 million in funding for the development of VIRALEZE provided by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality

VIRALEZE Antiviral Nasal Spray

VIRALEZE™ contains SPL7013, which has been shown in laboratory studies to inactivate a broad spectrum of respiratory/cold viruses, including multiple SARS-CoV-2 variants, influenza, and RSV. VIRALEZE™ is registered for sale in Europe, Vietnam, India and New Zealand. VIRALEZE™ is not registered for sale or supply in Australia.

SPL7013 is also included in other products registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand.

 

Download full announcement here: VIRALEZE™ registered in Vietnam with launch this week (PDF 214KB)

 

[1] NAM THANH MEDICAL CO., LTD (short name: NAMTHANH MSATCO; Business Registration Certificate No: 0107308573) is a supplier of medical products and equipment, including rapid COVID-19 test kits, based in Vietnam.

[2] https://covidvax.live/location/vnm

9354505000159

 This contains certain forward-looking statements.